Safest timing of pegfilgrastim administration seems to be 72 hours after chemo
the ONA take:
For the prevention of leukocytosis, the safest timing of pegfilgrastim administration based on white blood cell (WBC) count in patients receiving dose-dense anthracycline- and taxane-based regimens seems to be 72 hours following chemotherapy, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers sought to determine the safest timing of pegfilgrastim administration in dose-dense anthracycline- and taxane-based chemotherapy.
Researchers enrolled 41 patients and assigned them to receive pegfilgrastim 24 hours, 72 hours, or 96 hours after chemotherapy. Safety was determined by the occurrence of early and late leukocytosis and the behavior of WBCs.
Results showed that the occurrence of early leukocytosis was more common in the 24-hour cohort, while late leukocytosis occurred most frequently in the 96-hour cohort.
Researchers found that patients in the 24-hour group experienced the highest median value of WBC count 24 hours after pegfilgrastim administrated and those in the 96-hour group experienced the highest median value at day 13 in both chemotherapy cycles.
Safest timing of pegfilgrastim administration based on white blood cell count seems to be 72 hours following chemotherapy.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|